Session: Keynote Address

Opening Keynote Address - Identification of RIOK2 as a Master Regulator of Human Blood Cell Development

Wednesday, June 21, 2023

8:00 AM – 8:45 AM

Location: Salon F-G

Speaker(s)

Laurie H. Glimcher, MD

President & CEO
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Chair(s)

Megan Sykes, MD

Michael J. Friedlander Professor of Medicine and Professor of Microbiology and Immunology and Surgic
Columbia University
New York, New York, United States

Disclosure(s):

Laurie H. Glimcher, MD: Abpro Therapeutics: Consultant/Advisor (Ongoing); Analog Devices Board of Directors: Consultant/Advisor (Ongoing), Equity/Owner (Ongoing); Bristol Myers Squibb Board of Directors: Consultant/Advisor (Terminated, July 16, 2017), Equity/Owner (Terminated, July 16, 2017); GlaxoSmithKline Board of Directors: Consultant/Advisor (Terminated, October 13, 2022), Equity/Owner (Terminated, October 13, 2022); JPM Healthcare Advisory Fund: Consultant/Advisor (Ongoing); Repare Therapeutics: Consultant/Advisor (Ongoing); Waters Corp Board of Directors: Consultant/Advisor (Terminated, August 17, 2020), Equity/Owner (Terminated, August 17, 2020)

Learning Objectives:

Overview of anemia as a disease.
Summary of the role of IL-22 in anemia.
Summary of the function of the role of RIOK2 as master regulator of human blood cell development.